Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity.

Published

Journal Article (Review)

Treatment of severe retinopathy of prematurity (ROP) has evolved over the last decade. This article reviews recent clinical trials and experimental evidence that supports clinical outcomes and observations, including the efficacy of anti-vascular endothelial growth factor (VEGF) agents in reducing the vascular activity of severe ROP, and the mechanisms behind recurrent stage 3 ROP and plus disease in some infants treated with anti-VEGF agents. Also discussed will be current imaging modalities that link experimental models of ROP with longitudinal human studies and which provide exciting future opportunities to enhance the understanding of pathophysiology of ROP and improve treatments. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:228-234.].

Full Text

Duke Authors

Cited Authors

  • Hartnett, ME; Toth, CA

Published Date

  • April 1, 2019

Published In

Volume / Issue

  • 50 / 4

Start / End Page

  • 228 - 234

PubMed ID

  • 30998244

Pubmed Central ID

  • 30998244

Electronic International Standard Serial Number (EISSN)

  • 2325-8179

Digital Object Identifier (DOI)

  • 10.3928/23258160-20190401-05

Language

  • eng

Conference Location

  • United States